Conference Reports for NATAP

62th Annual Meeting of the American Association for the Study of Liver Diseases San Francisco 2011 Nov 6-9 Back

Evaluation of Drug Interaction Potential of the HCV Protease Inhibitor Asunaprevir (ASV; BMS-650032) at 200 mg Twice Daily (BID) in Metabolic Cocktail and P-glycoprotein (P-gp) Probe Studies in Healthy Volunteers       Reported by Jules Levin AASLD Nov 4-8 2011 SF   Eley T, Gardiner D, Persson A, He B, You X, Shah V, Sherman D, Kandoussi H, Sims K, Pasquinelli C, Bertz R Chengdu, China; 25The Second Affiliated Hospital